Illumina was among the returning investors for the round that will help Columbia spinout Kallyope prepare a weight loss treatment for clinical trials.
Kallyope, a US-based spinout of Columbia University developing drugs for conditions related to the gut and brain, raised $112m yesterday in a series C round featuring Illumina Ventures, the investment arm of genomics technology producer Illumina.
Alexandria Venture Investments, the venture capital unit of real estate investment trust Alexandria Real Estate Equities, also contributed to the round.
The company’s other existing backers, including Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures and philanthropist Bill Gates…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
